Compounds > niacinamide

niacinamide and quizartinib

niacinamide has been researched along with quizartinib in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (9.09)29.6817
2010's10 (90.91)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Armstrong, RC; Belli, B; Bhagwat, SS; Brigham, D; Chao, Q; Cramer, MD; Gardner, MF; Gunawardane, RN; James, J; Karaman, MW; Levis, M; Pallares, G; Patel, HK; Pratz, KW; Sprankle, KG; Zarrinkar, PP1
Levis, M; Murphy, KM; Pratz, KW; Rajkhowa, T; Sato, T; Stine, A1
Atrash, B; Avery, S; Bavetsias, V; Blagg, J; de Haven Brandon, A; Eccles, SA; Faisal, A; Gonzalez de Castro, D; Linardopoulos, S; Mair, D; Mirabella, F; Moore, AS; Pearson, AD; Raynaud, FI; Sun, C; Swansbury, J; Valenti, M; Workman, P1
Cortes, J; Daver, N1
Freeman, C; Giles, F; Swords, R1
Damon, LE; Lasater, EA; Lin, KC; Salerno, S; Shah, NP; Smith, CC; Stewart, WK; Zhu, X1
Alvarado, Y; Andreeff, M; Borthakur, G; Cortes, JE; Estrov, Z; Garcia-Manero, G; Kantarjian, HM; Konopleva, M; Luthra, R; Ravandi, F1
Andreeff, M; Cortes, J; Kantarjian, H; Pemmaraju, N; Ravandi, F1
D'Argenio, DZ; Hsu, CP; Huard, J; Kuchimanchi, M; Lu, JF; Ma, J; Sun, YN; Weidner, M; Xu, G; Xu, Y; Zhang, Y1
Galanis, A; Levis, M1
Chen, B; Cooper, JL; Dovey, OM; Friedrich, M; Grove, CS; Huang, Y; Lee, B; Mupo, A; Varela, I; Vassiliou, GS1

Reviews

3 review(s) available for niacinamide and quizartinib

ArticleYear
Molecular targeted therapy in acute myeloid leukemia.
    Hematology (Amsterdam, Netherlands), 2012, Volume: 17 Suppl 1

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; fms-Like Tyrosine Kinase 3; Humans; Janus Kinase 2; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; ras Proteins; Sorafenib; Staurosporine

2012
Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.
    Leukemia, 2012, Volume: 26, Issue:10

    Topics: Benzenesulfonates; Benzothiazoles; Carbazoles; CCAAT-Enhancer-Binding Protein-alpha; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Staurosporine

2012
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
    Expert opinion on investigational drugs, 2014, Volume: 23, Issue:7

    Topics: Animals; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridazines; Sorafenib; Staurosporine

2014

Other Studies

8 other study(ies) available for niacinamide and quizartinib

ArticleYear
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
    Blood, 2009, Oct-01, Volume: 114, Issue:14

    Topics: Animals; Benzenesulfonates; Benzothiazoles; Bone Marrow; Carbazoles; Cell Line, Tumor; Cell Proliferation; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Prognosis; Protein Interaction Mapping; Protein Kinase C; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Staurosporine; Xenograft Model Antitumor Assays

2009
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.
    Blood, 2010, Feb-18, Volume: 115, Issue:7

    Topics: Alleles; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; Carbazoles; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib

2010
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
    Leukemia, 2012, Volume: 26, Issue:7

    Topics: Animals; Apoptosis; Aurora Kinases; Benzenesulfonates; Benzothiazoles; Blotting, Western; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Quinazolines; Sorafenib; Tandem Repeat Sequences; Tumor Cells, Cultured

2012
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
    Blood, 2013, Apr-18, Volume: 121, Issue:16

    Topics: Amino Acid Sequence; Amino Acid Substitution; Benzothiazoles; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Molecular Docking Simulation; Molecular Sequence Data; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridazines; Quinolines; Sorafenib

2013
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
    Cancer, 2014, Jul-15, Volume: 120, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Carbazoles; DNA Mutational Analysis; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Male; Medical Records; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome

2014
FLT3 and CDK4/6 inhibitors: signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia.
    Journal of pharmacokinetics and pharmacodynamics, 2014, Volume: 41, Issue:6

    Topics: Animals; Benzothiazoles; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease Models, Animal; fms-Like Tyrosine Kinase 3; Leukemia, Myeloid, Acute; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Tumor Burden

2014
Inhibition of c-Kit by tyrosine kinase inhibitors.
    Haematologica, 2015, Volume: 100, Issue:3

    Topics: Aminopyridines; Antineoplastic Agents; Benzothiazoles; Biomarkers; Bone Marrow; Cell Line, Tumor; Clinical Trials as Topic; Dasatinib; fms-Like Tyrosine Kinase 3; Gene Expression; Hair; Hematopoietic Stem Cells; Humans; Indazoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Pigmentation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Thiazoles

2015
Identification of a germline F692L drug resistance variant in cis with Flt3-internal tandem duplication in knock-in mice.
    Haematologica, 2016, Volume: 101, Issue:8

    Topics: Animals; Benzothiazoles; Drug Resistance; fms-Like Tyrosine Kinase 3; Gene Knock-In Techniques; Germ-Line Mutation; Humans; Leukemia, Myeloid, Acute; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Tandem Repeat Sequences; Tumor Cells, Cultured

2016